• All fields are required unless indicated optional

  • 3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications which may include promotions, product information and service offers. Please be aware that this information may be stored on a server located in the U.S. If you do not consent to this use of your personal information, please do not use this system.

  • Submit

Our apologies...

An error has occurred while submitting. Please try again later...

Thank you!

Your form was submitted successfully

clinicians using Prevena on a patient's abdomen

Help advance the standard of care with 3M™ Prevena™ Therapy

The costly reality of at-risk incisions

  • In an increasingly complex healthcare environment, surgeons are faced with unique challenges that can negatively affect outcomes. Effectively managing the risk of postoperative complication is a priority.

    • Surgical site infections (SSIs) account for 22%–36% of all healthcare-associated infections (HAIs)1,2
    • Patients with an SSI are 6X more likely to have a 30-day readmission3
    • The average added cost from SSIs is $38,6564
    • A patient who develops an SSI has on average a 9.58 day longer hospital stay4
    • A patient who develops an SSI has on average a 2.2X longer ICU stay3

Implement Proactive Risk Management (PRM) with Prevena Therapy

Proactive Risk Management (PRM) with 3M™ Prevena™ Therapy provides healthcare professionals with an evidence-based, standardized approach that helps to advance the standard of care for closed incision negative pressure therapy (ciNPT). This intuitive, actionable model is grounded in level 1, 2 and 3 clinical evidence to help support you through procedural and patient risk stratification.


Proactively manage and help protect surgical incisions

This scientifically engineered, advanced dressing therapy is the first closed-incision negative pressure therapy (ciNPT) solution of its kind to help reduce the risk or incidence of seromas and superficial surgical site infections in Class I and II wounds.**

  • Prevena PRM Icon Reduction in SSCs
    Acts as a barrier to external contamination
  • Prevena PRM Icon Reduction in Readmission Rates
    Delivers continuous -125 mmHg up to 7 days
  • Prevena PRM Icon Reduction in per-patient cost of care
    Helps to hold incision edges together
  • Prevena PRM Icon Reduction in SSCs
    Decreases lateral tension of sutured/stapled incisions⁸

     

  • Prevena PRM Icon Reduction in Readmission Rates
    Removes fluids and infectious materials*

     

  • Prevena PRM Icon Reduction in per-patient cost of care
    Reduces edema

     

  • *In a canister
    **The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seromas in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at HCBGRegulatory.3m.com.

Help improve patient outcomes

In a newly published 2023 Multi-Specialty Meta-Analysis, Prevena Therapy has demonstrated significant improvement in key patient outcomes across multiple specialties.⁹

  • purple circle icon with
    46% Reduction in SSCs
  • purple circle icon with
    48% Reduction in SSIs

     

  • purple circle icon with
    36% Reduction in return to OR

     

  • purple circle icon with
    23% Reduction in readmission

     

Visit Prevena Central

Prevena Central is your one-stop platform for all things Prevena Therapy. Designed with busy healthcare professionals in mind, Prevena Central provides incision management resources that help advance the standard of care.

PRM Resources

Purple gradient
Interested in implementing PRM in your practice?

Contact a 3M representative for information or to request a demonstration.

CONTACT A REP

NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

3M™Prevena™ Therapy Indications for Use:
3M™Prevena™ 125 Therapy Unit and 3M™ Prevena™ Plus 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125 mmHg continuous negative pressure.

When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds. The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at hcbgregulatory.3m.com.

3M™ Prevena™ Restor™ Therapy Indications for Use: The 3M™ Prevena Restor™ Incision Management System is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy.

References
1.Zimlichman E, Henderson D, Tamir, et al. Health care-associated Infections a meta-analysis of costs and financial impact on the U.S. health care system. JAMA Interned.2013;173(22):20-46.
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated Infections. N Engl JMed: 2014;370:1198-208.
3. Shepard J, Ward W, Milstone A, et al. Financial impact of surgical site infections on hospitals. The hospital management perspective. JAMA Surg. 2013;148(10):907-914.doi:10.1001/jamasurg.2013.2246 Published online August 21, 2013.
4. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290(14):1868-1874.
5. Wilkes RP, Kilpadi DV, Zhao Y, et al. Closed Incision Management With Negative Pressure Wound Therapy (CIM): Biomechanics.Surgical Innovation. 2012;19(1):67-75.
6. Kilpadi DV, Cunningham MR. Evaluation of closed incision management with negative pressure wound therapy (CIM): hematoma/seroma and involvement of the lymphatic system. Wound Repair Regen. 2011;19(5):588-596.
7. Glaser DA, Farnsworth CL, Varley ES, et al. Negative pressure therapy for closed spine incisions: a pilot study. Wounds. 2012;24(11):308-316.
8. Wilkes RP, Kilpadi DV, Zhao Y, et al. Closed Incision Management With Negative Pressure Wound Therapy (CIM): Biomechanics. Surgical Innovation. 2012;19(1):67-75.
9. Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure Therapy Versus Standard of Care Over Closed Surgical Incisions in the Reduction of Surgical Site Complications: A Systematic Review and Meta-Analysis of Comparative Studies. Plastic and Reconstructive Surgery – Global Open. 2023 Mar 16;11(3):e4722.